TCR2 Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

TCR2 Therapeutics

10/11/2021 14:32

* TCR2 Therapeutics Inc  TCRR.OQ  reported a quarterly adjusted
loss of 69 cents​​ per share for the quarter ended in September.
The mean expectation of nine analysts for the quarter was for a
loss of 65 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* TCR2 Therapeutics Inc's reported EPS for the quarter was a
loss of 69 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* TCR2 Therapeutics Inc shares had fallen by 16.7% this
quarter and lost 77.1% so far this year.
* The company reported a quarterly loss of $26.24 million.
* Wall Street's median 12-month price target for TCR2
Therapeutics Inc is $25.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 10 at 02:32 p.m.
 ​All figures in US dollars unless otherwise stated